A recently developed CLL International Prognostic Index using age, clinical stage, TP53 status, IGHV mutation status, and serum β2-microglobulin has been shown to better predict progression in early CLL [2, 11]. The gene discussed is HLA-G; the disease is B-cell chronic lymphocytic leukemia.